文献速递心脑血管急症

直接凝血因子Xa抑制——利伐沙班在大鼠中具有心脏保护作用

Direct Rivaroxaban-Induced Factor XA Inhibition Proves to be Cardioprotective in Rats.
PubMed 文献 · Shock · 2020-01-01
一句话结论大鼠心肌缺血-再灌注模型中,再灌注前1小时口服利伐沙班3 mg/kg使梗死面积降低21%(42.9% vs 54.2%,P<0.05),血药浓度与人类治疗浓度相似,保护作用不依赖内皮表型调节而可能源于对心肌细胞的直接细胞保护。

该研究在大鼠40分钟冠脉结扎后再灌注模型中,于再灌注前1小时口服利伐沙班3 mg/kg。再灌注120分钟时,利伐沙班组梗死面积42.9%,对照组54.2%,降低21%(P<0.05),血药浓度387.7±152.3 ng/mL,与人类治疗浓度相似。利伐沙班未改变缺氧-复氧对内皮表型的调节,也未改变再灌注30分钟时心肌RISK和SAFE通路的激活,但对缺氧-复氧的H9c2大鼠心肌细胞有细胞保护作用。作者结论为利伐沙班在大鼠中减轻心肌缺血-再灌注损伤,该保护与内皮表型调节无关,而可能与对心肌细胞的直接细胞保护作用有关。

要点

  • 大鼠40分钟冠脉结扎后再灌注前1小时口服利伐沙班3 mg/kg,再灌注120分钟时梗死面积42.9% vs 对照组54.2%,降低21%(P<0.05)。
  • 起效血药浓度387.7±152.3 ng/mL,与人类治疗浓度相似。
  • 利伐沙班未改变缺氧-复氧诱导的内皮表型调节。
  • 再灌注30分钟时利伐沙班未改变心肌RISK和SAFE通路的激活。
  • 利伐沙班对缺氧-复氧的H9c2大鼠心肌细胞有细胞保护作用,作者认为保护可能源于对心肌细胞的直接细胞保护。

适用人群与场景

  • 大鼠在体心肌缺血-再灌注模型:40分钟冠脉结扎后复灌。
  • 体外缺氧-复氧模型:人脐静脉内皮细胞和大鼠心肌细胞(H9c2细胞系)。

处置流程与药物剂量

  • 利伐沙班3 mg/kg,再灌注前1小时经口给药(per os)。
  • 再灌注120分钟评估梗死面积,再灌注30分钟评估心肌存活通路蛋白表达,再灌注60分钟测血浆P-选择素和血管性血友病因子水平。

研究设计与关键结果

  • 研究类型:大鼠在体心肌缺血-再灌注实验及体外细胞缺氧-复氧实验。
  • 干预与对照:利伐沙班3 mg/kg再灌注前1小时口服 vs 对照。
  • 主要终点:再灌注120分钟梗死面积利伐沙班组42.9% vs 对照组54.2%,降低21%(P<0.05)。
  • 血药浓度:387.7±152.3 ng/mL,与人类治疗浓度相似。
  • 机制终点:再灌注30分钟时利伐沙班未改变心肌RISK和SAFE通路的激活;未改变缺氧-复氧诱导的内皮表型调节。
  • 细胞实验:利伐沙班对缺氧-复氧的H9c2大鼠心肌细胞有细胞保护作用。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠在体缺血-再灌注模型)及体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为利伐沙班在大鼠中减轻心肌缺血-再灌注损伤,该保护与内皮表型调节无关,而可能与对心肌细胞的直接细胞保护作用有关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute myocardial infarction is a leading cause of death worldwide. Though highly beneficial, reperfusion of myocardium is associated with reperfusion injury. While indirect inhibition of Factor Xa has been shown to attenuate myocardial ischemia-reperfusion (I/R) injury, the underlying mechanism remains unclear. Our study sought to evaluate the effect of rivaroxaban (RIV), a direct inhibitor of Factor Xa, on myocardial I/R injury and determine its cellular targets.

EXPERIMENTAL APPROACH: We used a rat model of 40-min coronary ligation followed by reperfusion. RIV (3 mg/kg) was given per os 1 h before reperfusion. Infarct size and myocardial proteic expression of survival pathways were assessed at 120 and 30 min of reperfusion, respectively. Plasmatic levels of P-selectin and von Willebrand factor were measured at 60 min of reperfusion. Cellular RIV effects were assessed using hypoxia-reoxygenation (H/R) models on human umbilical vein endothelial cells and on rat cardiomyoblasts (H9c2 cell line).

KEY RESULTS: RIV decreased infarct size by 21% (42.9% vs. 54.2% in RIV-treated rats and controls respectively, P < 0.05) at blood concentrations similar to human therapeutic (387.7 ± 152.3 ng/mL) levels. RIV had no effect on H/R-induced modulation of endothelial phenotype, nor did it alter myocardial activation of reperfusion injury salvage kinase and survivor activating factor enhancement pathways at 30 min after reperfusion. However, RIV exerted a cytoprotective effect on H9c2 cells submitted to H/R.

CONCLUSIONS: RIV decreased myocardial I/R injury in rats at concentrations similar to human therapeutic ones. This protection was not associated with endothelial phenotype modulation but rather with potential direct cytoprotection on cardiomyocytes.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Guillou S, Beaumont J, Tamareille S, et al. Direct Rivaroxaban-Induced Factor XA Inhibition Proves to be Cardioprotective in Rats. Shock. 2020. PMID: 31348147. doi:10.1097/SHK.0000000000001412

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。